Navigation Links
Possible drug target found for one of the most aggressive breast cancers
Date:7/8/2009

Grand Rapids, Mich. (July 8, 2009) Van Andel Research Institute (VARI) investigators have identified a gene that could be an important therapeutic target in the treatment of the most aggressive forms of breast cancer. Currently, patients with these cancers have few treatment options.

"Breast cancer mortality rates are actually declining, but the cancers that don't respond to traditional treatments tend to be more aggressive and have decreased survival rates," said VARI Research Scientist Carrie Graveel, Ph.D., lead author of the study published this week in Proceedings of the National Academy of Sciences U.S.A.

Researchers found that the Met gene may play a critical role in the development of an aggressive form of breast cancer known as basal breast cancer.

"Met has already been associated with decreased survival in breast cancer, but this study identifies its importance in specific types that can be distinguished at the molecular level," said VARI Distinguished Scientific Fellow George Vande Woude, Ph.D., who heads the laboratory that conducted the research.

In the 1980's, Dr. Vande Woude's laboratory at the National Cancer Institute demonstrated that inappropriate levels of Met occur in human tumors, and that cells with inappropriate Met signaling dramatically impact the spread of cancer. This signaling is implicated in most types of human cancers and high Met expression often correlates with poor prognosis.

"We found Met in the majority of breast cancers," said VARI Research Technician Jack DeGroot, another of the study's authors. "But levels were highest in aggressive types, making Met a promising drug target that could help patients that currently have few treatment options."

According to the American Cancer Society, breast cancers account for more than one in four cancers diagnosed in women in the United States. The National Cancer Institute estimates that 40,170 women in the U.S. will die from breast cancer in 2009.

"This very exciting work by the Van Andel Research Institute gives us a new target for treatment of patients with one of the worst types of breast cancer basal breast cancer," said Dr. Daniel D. Von Hoff, Physician-in Chief of the Translational Genomic Research Institute (TGen) in Phoenix, Arizona, which initiated an alliance with Van Andel Institute in February. "Since there are many new inhibitors of Met available for clinical trials, we now have a direct route for immediate application of these important findings in the care of patients with this very aggressive form of breast cancer."


'/>"/>

Contact: Joe Gavan
616-234-5390
Van Andel Research Institute
Source:Eurekalert

Related biology news :

1. New dinosaur species possible in Northwestern Alberta
2. Study validates means to measure possible leukemia marker
3. Bovine genome provides clues to possible new developments
4. Ultrasound imaging now possible with a smartphone
5. TGen researchers discover possible way to block the spread of deadly brain tumors
6. New high-throughput screening technique makes probing puzzling proteins possible
7. Peptides-on-demand: McGill researchers radical new green chemistry makes the impossible possible
8. A research work on molluscs nacre opens new doors for its possible use in biomedicine
9. Scientists unlock possible aging secret in genetically altered fruit fly
10. Control of blood vessels a possible weapon against obesity
11. Promising new drug being evaluated as possible treatment option for fragile X syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: